Here, we report the results of a phase Ib dose escalation study (Fig. 1a) evaluating safety and tolerability of ITPP to define a maximum tolerated dose (MTD), analyze the pharmacokinetics of increasing ITPP doses, and estimating the efficacy in patients with unresectable primary malignancies of the liver, pancreas and biliary tract or liver metastases of colorectal cancer. This evidence concerns the gene TPP1 and colorectal cancer.